🧠 Chronic Traumatic Encephalopathy Risk Awareness Simulator

What Is Chronic Traumatic Encephalopathy?

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease characterized by the abnormal accumulation of hyperphosphorylated tau protein in the brain. It is associated with a history of repetitive head impacts (RHI) — and, importantly, research increasingly emphasizes that subconcussive impacts, which produce no diagnosed concussion or obvious symptoms at the time, may contribute to cumulative exposure alongside clinically diagnosed concussions. At present, CTE can only be diagnosed definitively through postmortem neuropathological examination of brain tissue; there is no validated imaging test or fluid biomarker that can diagnose it in a living person.

• "Dementia Pugilistica": Historical name (Martland, 1928, described in boxers)
• Hyperphosphorylated tau: Defining pathology (abnormal protein accumulation)
• Concussive + subconcussive RHI: Exposure implicated (not just diagnosed concussions)
• None exists: Validated living diagnosis (postmortem exam only, as of current research)

A tauopathy associated with repetitive head impact exposure

CTE belongs to a family of diseases called tauopathies, in which the microtubule-associated protein tau becomes abnormally hyperphosphorylated, misfolds, and aggregates inside neurons and astrocytes. Under normal conditions, tau stabilizes microtubules that form part of a neuron's internal transport scaffolding. When hyperphosphorylated, tau detaches from microtubules, aggregates into insoluble filaments, and disrupts normal cell function and axonal transport.

What distinguishes CTE from other tauopathies (like Alzheimer's disease) is not just the presence of tau pathology, but its distinctive anatomical distribution and its association with a specific exposure history: repetitive mechanical trauma to the brain, typically accumulated over years of participation in contact or collision sports, military service involving blast exposure, or other repeated head-impact activities.

The disease was first described in 1928 by pathologist Harrison Martland, who used the term "punch drunk syndrome" (later formalized as "dementia pugilistica") to describe a constellation of neurological changes observed in retired boxers. The modern name "chronic traumatic encephalopathy" and its associated neuropathological criteria emerged from decades of subsequent case study, particularly research on American football players, hockey players, and military veterans.

Why "no symptoms at the time" does not mean "no exposure"

A key concept in current CTE research is the distinction between concussion (a clinically diagnosed brain injury with overt, observable symptoms) and subconcussive impact (a head impact that does not produce diagnosable symptoms but still transmits mechanical force to brain tissue). Athletes in contact sports may sustain hundreds to thousands of subconcussive head impacts across a single season — for example, offensive linemen in American football experience head contact on nearly every play, most of which never rise to the level of a diagnosed concussion.

Researchers hypothesize that the cumulative burden of these many smaller, often unnoticed impacts — not just the relatively rare diagnosed concussions — may be mechanistically relevant to the later development of tau pathology. This is why researchers increasingly describe RHI exposure in terms of cumulative impact counts and years of exposure, rather than concussion counts alone, when studying possible contributing factors.

This framing matters for prevention: strategies that only intervene after a diagnosed concussion (like return-to-play protocols) may not address the much larger volume of subconcussive exposure that occurs during ordinary practice and play.

What CTE research does not yet allow us to say

It is important to be precise about the current limits of scientific knowledge. CTE has been characterized through postmortem neuropathological study, primarily in brains donated by individuals or families concerned about symptoms possibly linked to a history of head-impact exposure. This is a powerful way to characterize pathology, but it does not, by itself, establish how common CTE is in the broader population of contact-sport participants, what the precise dose-response relationship with exposure looks like, or which specific individuals are most likely to develop the disease.

Important: CTE cannot currently be diagnosed in a living person. There is no validated in-vivo biomarker, blood test, or imaging scan approved for this purpose. This simulator is an educational illustration of proposed research concepts — the diagrams, "confidence" indicators, and exposure scores are illustrative teaching aids, not a diagnostic tool, a risk-prediction tool, or a substitute for medical or scientific guidance.

The Neuropathological Diagnostic Criteria for CTE

CTE is currently defined and diagnosed exclusively through postmortem neuropathological examination, guided by consensus criteria developed by a NINDS-convened panel of expert neuropathologists (McKee et al., 2016). These criteria specify a single required, pathognomonic lesion — a lesion pattern that, when identified, is considered diagnostic of CTE and distinguishes it from other neurodegenerative tauopathies such as Alzheimer's disease.

• 2016: Consensus criteria published (NINDS-convened panel; McKee et al., Acta Neuropathologica)
• Perivascular p-tau: Pathognomonic lesion (at the depths of cortical sulci)
• Stage I – IV: Staging system (reflects anatomic spread and severity)
• Alzheimer's disease tau: Distinguished from (different regional distribution pattern)

The pathognomonic lesion: perivascular tau at sulcal depths

The defining, required lesion for a neuropathological diagnosis of CTE is a specific pattern: irregular, patchy accumulation of hyperphosphorylated tau in neurons and astrocytes, concentrated around small blood vessels (perivascular), located preferentially at the depths of the cortical sulci — the valleys between the folds (gyri) of the cerebral cortex — often at the depths of sulci in a periodic, irregular pattern rather than being diffusely spread across the entire cortical surface.

This distribution pattern is what allows neuropathologists to distinguish CTE tau pathology from other tauopathies. In Alzheimer's disease, for example, tau pathology (neurofibrillary tangles) typically follows a more diffuse, layered cortical distribution and is closely associated with amyloid-beta plaque pathology — a co-pathology that is not a required or defining feature of CTE. The perivascular, sulcal-depth-predominant distribution seen in CTE is thought to reflect the biomechanics of brain injury: rotational and linear acceleration forces during head impact are believed to generate greater shear stress at sulcal depths and around penetrating blood vessels than at the crests of gyri.

This lesion is only identifiable by direct microscopic examination of brain tissue sections stained for phosphorylated tau (commonly using antibodies such as AT8). There is currently no imaging modality validated to visualize this specific pattern in a living patient with the accuracy required for diagnosis.

The Stage I–IV progression observed at autopsy

The McKee staging scheme describes four progressive stages of pathological severity and anatomical spread, observed across a spectrum of postmortem brains studied to date:

Stage I — Isolated, focal epicenters of perivascular p-tau pathology at the depths of a small number of cortical sulci, often in the frontal cortex. Typically no gross (macroscopic) brain changes are visible at this stage.

Stage II — Multiple discrete epicenters of pathology across a larger number of sulci, still generally localized to the frontal and, sometimes, temporal cortex, without widespread involvement.

Stage III — More widespread cortical involvement including additional cortical regions, medial temporal lobe structures (amygdala, hippocampus, entorhinal cortex), diencephalon, and brainstem; mild gross atrophy may become visible.

Stage IV — Severe, widespread pathology throughout the cerebral cortex, medial temporal lobe, diencephalon, and brainstem, frequently accompanied by macroscopic brain atrophy, ventricular enlargement, and pronounced neuronal loss.

This staging system describes what has been observed pathologically at autopsy across studied cases; it characterizes anatomic severity of pathology found after death and is not itself a tool for predicting or measuring pathology in a living person.

Distinguishing CTE from other neurodegenerative tauopathies

Neuropathologists must carefully rule out or characterize co-occurring pathologies when examining donated brain tissue, since many neurodegenerative conditions can co-exist in the same brain, particularly in older individuals. Alzheimer's disease neuropathologic change, Lewy body disease, TDP-43 proteinopathy, and cerebrovascular disease can all occur alongside CTE pathology, and careful, criteria-based differentiation is required to avoid misattributing findings.

This diagnostic rigor is one reason why the NINDS consensus criteria process was significant: prior to 2016, published case reports used varying informal definitions, making it difficult to compare findings across research groups or estimate consistent pathological criteria. The consensus criteria created a shared, reproducible standard for neuropathological diagnosis — a necessary (though not sufficient) foundation for any future effort to correlate pathology with antemortem clinical presentation.

Proposed Clinical Presentation & Its Scientific Uncertainty

Retrospective case series of individuals with autopsy-confirmed CTE pathology have reported a range of clinical features observed during life, including mood and behavioral changes, cognitive impairment, and — in more advanced pathological stages — motor symptoms. However, a critical scientific caveat must accompany any discussion of these reported features: a validated, prospectively-confirmed clinical CTE syndrome that reliably links specific living symptoms to eventual pathology has NOT yet been established.

• Mood, cognition, motor: Reported symptom domains (from retrospective case series only)
• Not yet established: Validated clinical syndrome (no prospective, confirmed diagnostic link)
• "TES" criteria: Research framework (2021) (a research construct, not a clinical diagnosis)
• Selection / referral bias: Major limitation (donor cohorts are not representative samples)

Symptom domains reported in retrospective case series

Published case series of individuals with autopsy-confirmed CTE pathology — most prominently from brain banks such as the one at Boston University — have described antemortem symptoms falling into roughly three domains:

Mood and behavioral changes: reported features include depression, apathy, irritability, impulsivity, aggression, and, in some case reports, suicidality.

Cognitive impairment: reported features include difficulties with memory, executive function (planning, judgment, impulse control), attention, and processing speed, sometimes progressing to a dementia-like clinical picture in advanced cases.

Motor symptoms: reported primarily in more advanced pathological stages, including parkinsonism-like features (rigidity, gait disturbance, tremor) and, in some reports, motor neuron disease-like features.

These descriptions come from careful clinical history-taking, often obtained retrospectively from family members after the individual's death, cross-referenced against the pathological findings at autopsy.

The critical caveat: no validated living-diagnosis clinical syndrome

Despite the pattern of reported symptoms above, it has not been scientifically established that these symptoms — individually or in combination — reliably predict, in a living person, that CTE pathology will be found at autopsy. In 2021, a research consensus group proposed diagnostic criteria for a clinical research construct called Traumatic Encephalopathy Syndrome (TES), intended explicitly as a research framework to standardize study of possible clinical correlates of RHI exposure — not as a validated clinical diagnosis of CTE itself, and not as a tool cleared for individual diagnostic or predictive use.

The distinction matters enormously: a research framework designed to help scientists study a possible relationship in a standardized way is fundamentally different from a validated diagnostic test with established sensitivity, specificity, and predictive value in individual patients. As of current research, no clinical symptom, symptom cluster, or combination of neuropsychological test results has been shown, in prospective studies, to reliably predict autopsy-confirmed CTE pathology.

Selection bias in brain donation-based case series

A major limitation of the existing evidence base is that brain donation programs supporting CTE research predominantly enroll donors — or families who register a loved one — because of pre-existing concern about symptoms possibly related to head-impact history, media attention, or contact with advocacy and support organizations. This creates substantial selection (ascertainment) bias: individuals or families who suspect a problem are systematically more likely to participate in donation than those from the same exposure background who never developed symptoms of concern.

This bias means published case series cannot be used to estimate how common CTE pathology is among all individuals with a given level of head-impact exposure (true prevalence), nor can they establish a reliable causal dose-response curve, because the denominator — the full population of exposed individuals, including all those without concerning symptoms who never donate — is essentially unmeasured. Recognizing this limitation is not a dismissal of the underlying biological findings; it is a necessary constraint on what conclusions the current evidence can support about prevalence and individual risk.

Research Limitations & Ongoing Scientific Uncertainty

Beyond the specific caveats around clinical presentation, several fundamental scientific questions about CTE remain genuinely open. These are not settled matters awaiting popularization — they are active areas of investigation where the honest answer, today, is "we do not yet know," and where large, well-designed, prospective research studies are specifically designed to close these gaps.

• Unknown: True population prevalence (no representative population-based study exists)
• Not established: Dose-response relationship (exposure quantification remains difficult)
• Under active study: Genetic / risk modifiers (e.g., APOE genotype, age of first exposure)
• DIAGNOSE CTE: Leading longitudinal study (NIH-funded multi-site research project)

Unresolved questions of prevalence and dose-response

Two of the most basic epidemiological questions about CTE remain unanswered by current research: How common is CTE pathology among people with varying levels and types of repetitive head impact exposure (true prevalence)? And what is the quantitative relationship between exposure — measured in cumulative impacts, years of play, position played, level of competition, or age of first exposure — and the likelihood or severity of eventual pathology (dose-response)?

Answering these questions requires representative, prospectively-designed cohort studies that enroll participants based on their exposure history (not their symptom concerns), follow them over time, and — ideally — correlate detailed exposure measurement with eventual neuropathological findings, generally requiring brain donation at the end of life regardless of whether symptoms developed. Because most existing published cohorts are donation-based and subject to the selection bias described earlier, they cannot substitute for this kind of representative study design.

Why do some exposed individuals develop pathology and others do not?

A striking and still poorly understood observation in the existing literature is that individuals with seemingly similar histories of repetitive head impact exposure can show very different pathological outcomes — some with extensive, high-stage tau pathology at autopsy, others with minimal or no detectable pathology despite comparably long or intense exposure histories. This heterogeneity suggests that exposure alone is unlikely to be the sole determinant of risk, and that other factors modify individual susceptibility.

Candidate risk-modifying factors under active investigation include genetic variants (such as APOE genotype, which is also implicated in Alzheimer's disease risk), age at first exposure, total lifetime exposure duration, individual differences in brain vasculature or blood-brain barrier integrity, sleep, cardiovascular health, and other comorbid conditions. None of these factors has yet been validated as a reliable individual risk-stratification tool, but identifying them is a major research priority, since it could eventually help explain the variability in outcomes and potentially identify individuals who might benefit from more conservative exposure guidance.

The search for in-vivo biomarkers and major ongoing research efforts

A central research priority is developing a validated way to detect or infer CTE-associated pathology in living individuals — an in-vivo biomarker. Several approaches are under active investigation:

PET tau imaging: positron emission tomography tracers designed to bind tau protein (originally developed and validated primarily for Alzheimer's disease-associated tau conformations) are being studied for their ability to detect the specific tau conformations and distribution associated with CTE; results to date have been informative for research but are not validated for individual clinical diagnosis.

Blood and cerebrospinal fluid (CSF) biomarkers: candidate markers such as tau fragments, neurofilament light chain, and glial fibrillary acidic protein are under study as possible indicators of neurodegeneration or head-impact-related brain changes, but none is validated as specific to CTE.

The DIAGNOSE CTE Research Project, a major NIH-funded, multi-site longitudinal study, is following former American football players and other contact-sport athletes over time, combining clinical assessment, advanced imaging, and fluid biomarker collection, with the explicit goal of establishing clearer clinical-pathological correlation and validating candidate in-vivo biomarkers — precisely the kind of prospective, representative study design needed to resolve the open questions above.

Practical Risk Communication & Prevention Focus

Given the genuine and substantial diagnostic and scientific limitations described in the previous stages, responsible communication about CTE must walk a careful line: avoiding over-claiming individual diagnosis or risk prediction, while still supporting exposure-reduction strategies that carry sound rationale independent of the remaining CTE-specific uncertainty — because reducing head-impact exposure and following concussion protocols carry established benefits on their own terms.

• Evidence-backed: Contact-practice limits (measurably reduce head-impact exposure counts)
• Delay studied as strategy: Youth tackle introduction (reduces cumulative exposure-years)
• Established benefit: Concussion protocol adherence (reduces reinjury and recovery risk)
• Directly advances research: Brain donation / registries (e.g., Concussion Legacy Foundation registry)

Communicating uncertainty honestly, without minimizing the underlying concern

Responsible risk communication about CTE requires holding two things true at once: the underlying neuropathological findings are real and well-documented in the cases that have been studied, and yet the tools to translate those findings into an individual diagnosis, prognosis, or risk score for a living person do not currently exist. Overstating certainty — telling an individual athlete or parent that a given exposure history "will" or "will not" cause CTE, or that a given symptom "means" CTE — is not supported by current science and can cause real harm, whether through unwarranted alarm or false reassurance.

At the same time, acknowledging uncertainty is not the same as recommending inaction. Many exposure-reduction and safety strategies have their own independent evidentiary support — for concussion prevention, symptom management, and general safety — regardless of how the CTE-specific research questions are eventually resolved.

Exposure-reduction strategies with sound, independent rationale

Several practical strategies are supported by evidence for reducing head-impact exposure and improving player safety, independent of unresolved CTE-specific questions:

Practice contact limits: numerous youth, high school, and professional sport organizations have adopted policies limiting the amount and intensity of full-contact practice repetitions per week, which have been shown to measurably reduce the number of head impacts athletes sustain during a season.

Rule changes reducing head-contact frequency: modifications such as kickoff rule changes, restrictions on leading with the head, and stricter enforcement of targeting penalties are designed to reduce the frequency of high-magnitude head impacts during competition.

Coaching technique modification: teaching tackling and blocking techniques that emphasize shoulder contact and reduce head-first contact has been associated with reductions in measured head-impact exposure in studied cohorts.

Delayed introduction to tackle football in youth: some research and policy discussions have explored delaying the age at which children begin tackle (as opposed to flag or non-contact) football, on the rationale that reducing total cumulative exposure-years, particularly during early brain development, is a reasonable precautionary strategy even absent a fully established dose-response curve.

Concussion protocols and supporting continued research

Rigorous adherence to established concussion protocols — including immediate removal from play upon suspected concussion, structured medical evaluation, and graduated, symptom-guided return-to-play and return-to-learn progression — has well-established benefits for reducing the risk of prolonged recovery and second-impact complications, independent of any CTE-specific claims.

Finally, one of the most direct ways individuals and families can contribute to resolving the open scientific questions described in this simulator is by supporting and participating in ongoing research: enrolling in longitudinal studies such as the DIAGNOSE CTE Research Project, and considering brain donation registries such as the one maintained by the Concussion Legacy Foundation in partnership with research brain banks. Every additional prospectively-studied case — donated regardless of whether the individual developed symptoms — helps address the selection-bias limitations described in Stage 3 and moves the field closer to validated in-vivo biomarkers and a clearer understanding of true risk.

Reminder: CTE cannot currently be diagnosed in a living person, and this simulator does not diagnose, predict, or score individual risk. Its sliders and metrics are illustrative teaching aids representing research concepts and open questions — for education only, not medical or diagnostic guidance. Consult qualified medical and scientific professionals for individual concerns.